Abstract：Objective To investigate the effect of Imrecoxib combined with arthroscopic debridement in the treatment of knee osteoarthritis (KOA). Methods From March 2016 to April 2018, 102 patients with KOA admitted to Dalian Second People′s Hospital of were selected as subjects. According to the random number table method, the patients were divided into the control group (arthroscopic debridement + postoperative placebo treatment, n = 51) and the observation group (arthroscopic debridement + postoperative Imrecoxib treatment, n = 51), with a course of 2 months. The clinical curative effect, joint pain visual simwlation score (VAS) and function Lysholm scors, serum interleukin 1 (IL-1), IL-1β (IL-1β) and tumor necrosis factor -α (TNF-α) levels, joint fluid in the metal matrix protease-2 (MMP-2), matrix metalloproteinases inhibitor protease 1 (TIMP-1) and metal matrix-13 (MMP-13) level changes and the incidence of adverse reactions during treatment of the two groups were compared. Results The total effective rate in the observation group was higher than that in the control group (P ＜ 0.05). VAS scores in both groups were lower after treatment than before treatment, and VAS scores in the observation group were lower than those in the control group (P ＜ 0.05). Lysholm scores in both groups were increased after treatment, and the observation group was higher than the control group (P ＜ 0.05). After treatment, IL-1 and TNF-α in both groups were lower than that before treatment, and those in the observation group were lower than those in the control group (P ＜ 0.05). After treatment, IL-1β in both groups was higher than that before treatment, and that in the observation group was higher than that in the control group (P ＜ 0.05). After treatment, MMP-2, TIMP-1 and MMP-13 in both groups were lower than that before treatment, while those in the observation group were lower than those in the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Imrecoxib combined with arthroscopic debridement is effective in the treatment of KOA, which can reduce pain, improve knee function, lower exudation of inflammatory mediators and the levels of MMP-2 and MMP-13 in articular fluid.
2019, Vol. 16 
京公网安备 11010502046598号